For example, in the pre-clinical setting, the pan-RAF inhibitor LY3009120 showed pro-apoptotic and anti-proliferative effects in FLT3- and RAS-mutated AML cells [146] and effects in AML cells were even enhanced when combining LY3009120 with a BCL-2 inhibitor [147] or sorafenib [146]. The gene discussed is BCL2; the disease is acute myeloid leukemia.